DOCSLIB.ORG

NCI/Tufts University

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Where do viruses come from and why do they do what they do? John M. Coffin Tufts University Tufts University Where did viruses come from? (Actually, I haven’t a clue.) RNA world “RNA cell” Prokaryotes Eukaryotes Proto cell Why do they do what they do? (Because they can.) 1. However they arose, they have evolved multiple times into a variety of niches. 2. 2 Phases – virion and intracellular. 3. Rely on cell for most or all replicative functions. 4. Virion allows cell-cell and host-host transmission. 5. Their “job” is to direct cells to make more of themselves, not to cause disease (unless it promotes transmission). 6. Long term host-virus co evolution often leads to a well- adapted, relatively benign interaction. 7. Unlike most other viruses, retroviruses have left behind a fossil record that lets us study this evolution. The Retrovirus Replication Cycle Entry via fusion Adsorbtion to specific receptor (CD4) Maturation via protease The Retrovirus Family Tree Virus Genus HFV Spumaretrovirinae b e l1 , b e l2 MLV Gammaretrovirus FeLV HERV-C WDSV Epsilonretrovirus o rf A , o rf B , o rf C HIV-1 t a t , re v HIV-2 Lentivirus EIAV VMV d u t MPMV s a g n e w e n v MMTV Betaretrovirus HERV-K IAP ASLV Alpharetrovirus BLV HTLV-1 Deltaretrovirus t a x , re x HTLV-2 New Genes" At least 30 million years ago!" Endogenous Retroviruses 1. Remnants of germ line infections by exogenous (infectious) retroviruses. 2. Became fixed in the host species. Some confer protection against future infections by the same or similar viruses. A few others have salutary effects. 3. Inherited like normal genes. 4. Present in every vertebrate and many invertebrates. 5. Comprise 6-8% of the human genome. (More viruses than us). Endogenous Retroviruses 6. Provide a fossil record of pathogen-host interaction unavailable in any other system. 7. Can participate in evolutionary processes as well as inform us about them. 8. Involved in disease in some animals. Humans? Formation of Endogenous Proviruses Long terminal repeats (LTR’s) provirus Identical sequence Endogenous provirus Host-Virus Evolution ++ Host-Retrovirus Evolution Effects of Endogenous Proviruses (Good and Bad) Syncytin env Endogenous Retroviruses" and Primate Evolution! Endogenous Proviruses as Evolutionary Markers! 1. Represent unique and irreversible mutations:! • Shared insertions indicate common ancestry.! 2. Can be used to provide important evolutionary information:! • Estimate time of integration.! • Detect and quantitate various kinds of events! • Detect various kinds of recombination events. ! ! HERV-K (HML-2) Group 1. First entered genome more than 30 million years ago; successive waves of spread through our ancestors.! ! 2. There are <100 full-length proviruses in each of us, as well as about 900 solo LTR’s.! 3. Expressed as transcripts and particles in certain normal tissues and disease states.! ! 3. Mining from the human genome sequence: ! !• 91 full (or near full) length proviruses have been found! !• Most are fixed in our genomes; a few are polymorphic.! ! HERV-K (HML-2) proviruses! • Many have retained ORF! ! • Insertional polymorphisms! • Could be circulating at low rate (unknown)! ! • No provirus has been shown to be infectious as-is! Bhardwaj N, Coffin JM. Cell Host Microbe. 2014 Mar 12;15(3):255-9.! Evolution of HERV-K (HML-2) 1. From the pattern of mutations in the LTRs of a single provirus, we can also estimate:! !• its age.! !• the phylogeny of its host species.! 2. We can also detect various kinds of mutation and recombination events.! Endogenous Proviruses and Identical Primate Phylogeny integration site 5 Millions of years 8 Human ago Chimpanzee 12 Bonobo 18 2 30 Gorilla > 45 Orangutan Gibbon Old World Stump-tailed macaque Rhesus macaque Baboon African green monkey New World Squirrel monkey Evolution of HERV-K LTRs 5’ LTR 3’ LTR Mutations accumulate •• •• •! Species arise •• •• •! •• •• •! Mutations accumulate ••• • •• ••!! ••••• •••••! 5’ LTRs 3’ LTRs HERV-K19q13 74 Human 5'! Chimpanzee 5'! Bonobo 5'! 7 7 Gorilla 5'! Orangutan 5'! Gibbon 5'! Human 3'! Chimpanzee 3'! 7 9 Bonobo 3'! Gorilla 3'! Orangutan 3'! Gibbon 3'! HERV-K10 5'! HERV-K10 3'! MP, = 5 subst. HERV-K20q 9 Human 5'! 4 Gorilla 5'! Orangutan 5'! Chimpanzee 5'! Bonobo 5'! Human 3'! 7 74 3 Chimpanzee 3'! Bonobo 3'! 7 Gorilla 3' 9 Orangutan 3'! Baboon 3'! Af Gr Monkey 3'! HERV-K10 5'! HERV-K10 3'! MP, = 5 subst. Polymorphism of HERV-K 11q22 ! ! ! ! Provirus ! ! ! Donor ! ! Biaka Mbuti Maya Quecha Khmer Druze Ami 1 2 3 4 5 6 7 8 910 Adygei X Solo LTR 1. Frequent solo LTR formation. Empty site 2. Far flung groups have empty sites, implying integration more than a few hundred thousand years ago. ! Are Any HERVs Still Active? • Can we see differences in provirus content among individuals? Predicted bands Oligonucleotide Donor: probe 1 2 3 4 5 6 7 8 9 10 AseI Sites * * HERVs Extracted from the Human Genome • 91 “Full-length” (2-LTR)! • Ca 900 solo LTRs! • A few polymorphic! • Only one is complete! (but not infectious)! ! Subramanian et al. 2013! ! Rarer proviruses are more likely to be recently integrated, and perhaps retain infectivity.! Are there Recently Active Proviruses?! 1. In humans, there is much less evidence for recent activity of endogenous proviruses than in mice.! 2. Nevertheless, there have been a few new insertions of HERV-K’s within the last few hundred thousand years and some may still be capable of infection. ! 3. Such proviruses would be expected to be rare and perhaps confined to a small population.! 4. They might be seen in the “thousand genomes” project, a databse of over 2500 human genomes from populations worldwide.! However, the way the “sequencing is done (alignment of short reads to a reference genome) causes rearranged sequences like proviruses, to be discarded. Fortunately, they are saved in a non- aligned “dumpster” file.! ! Frequency ! 10 20 30 40 50 60 70 80 90 0 4p16a 10q26.3 12q24.32 3q11.2 Newly Found ProvirusesNewly 8q24.3 6p22.3 5p15.32 7q36.3 2-LTR Proviruses LTRs) solo (All2-LTR are the rest 19p12d 1q41 19q13.43 9q34 Provirus Xq21.33 4p16b 5q14.1 20p12.1 ! 1p21.1 11q12.2 5q12.3 13q31.3 12q24.31 19p12b 12q12 ! 6p21.32 19q12 19p12e 1p13.2 6q26 15q22.2 ! Structures of Newly Found 2-LTR Proviruses! Can Xq21,33 be the infectious provirus we are looking for?! • Relatively recently inserted! • All reading frames intact with no obvious muations! • Rare in the population (ca 1.5%) and geographically limited (Africa)! ! We’ll see…! HML-2 expression in different diseases! • RNA, protein and/or particles seen in many types of disease:! – Teratocarcinoma (pictured)! – Melanoma! – Breast cancer! – Lymphoma! – Multiple sclerosis! – ALS! – HIV-1 infection! – Normal Placenta! – Hypothesis: The expression pattern reflects the natural history of the ancestral virus (parent to child transmission)! Scale Bar = 250nm.! Bieda et al. J Gen Virol. 2001; 82:591-6.! Potential application of HML-2 expression! • Therapeutics designed to target HML-2 epitopes! – HML-2 epitopes could present an unchanging marker for infection if specifically expressed on infected/ diseased cells! – Vaccine to elicit anti-HML-2 Env and Gag responses in HIV-1 infection (Sacha et al., 2012; Shephard et al., 2014)! – HML-2 Env monoclonal Ab to target breast cancer cells (Wang-Johanning et al., 2012)! – Elicit anti-HML-2 Env T-cell responses to target ovarian cancer cells (Rycaj et al., 2015)! ! HML-2 RNA Reported in HIV-1 plasma! 30,000 copies/mL HIV RNA! Contreras-Galindo et al. Genome Res.2013;23(9):1505-13.! HML-2 RNA is not detected in HIV-1 plasma Uninfected! HIV-1 infected! Bhardwaj N, Maldarelli F, Mellors J, Coffin JM. J Virol. 2014;88(19):11108-20.! HML-2 RNA is upregulated in PBMCs Bhardwaj N, Maldarelli F, Mellors J, Coffin JM. J Virol. 2014;88(19):11108-20.! Possibility of HML-2 recombination! 3. Recombination! * * * * *! *! *! *! 2. Co-packaged RNA ! “a”! *! gag-pro-pol ! *! ! *! env “ab”! “b”! *! gag-pro-pol-env 1. Complementation! ! 4. Cell produces! infectious virus! Possibility of HML-2 recombination! • In-vitro recombinant HML-2 viruses are weakly infectious! – Recombination between 3 provirus genomes could lead to functional virus (Dewannieux et al., 2006; Lee et al., 2007)! • HML-2 expression in HIV-1 patients may lead to expression of proviruses with functional ORFs! – Need to profile which proviruses are expressed! ! Conclusions! 1. Retroviruses have uniquely left behind a rich fossil record of their (relatively) recent (30+ million year) coevolution with their host animals.! 2. All of the tens of thousands of known HERVs are incapable of replication and most are very old (>5 million years).! 3. Nevertheless, there have been a few new insertions of HML-2’s within the last few hundred thousand years and some may still be capable of infection. (Maybe we’ve found one.)! 4. HML-2 expression is upregulated in HIV-infected patient PBMCs (but no virus in blood!).! ! 5. Are any of polymorphic proviruses associated with disease, such as breast cancer? (We’re working on it.)! ! Acknowledgements -Jenn Hughes -Julia Wildschutte -Ravi Subramanian -Neeru Bhardwaj -Zachary Williams -Meaghan Montesion Tufts University Acknowledgements -Mary Kearney -Ann Wiegand -Jon Spindler -Wei Shao HIV Drug Resistance Program National Cancer Institute at Frederick Phylogeny of HML-2 proviruses gag LTRHs LTR5B LTR5A Subramanian RP, Wildschutte JH, Russo C, Coffin JM. Retrovirology. 2011;8:90. Profile HML-2 expression using RNASeq • Use RNASeq to: – Identify proviruses that could recombine to make a functional virus – Determine how expression changes between individuals • Advantages of total RNASeq: – Analyze expression in the context of other genes – No primer bias introduced – Long read lengths allow for unique read placement Profile HML-2 Expression Using RNASeq • Validate RNASeq on the teratocarcinoma cell line Tera-1 – Known to express HML-2 RNA and protein in cells – Produces non-infectious HML-2 virions – Perform RNASeq on passage-matched cell and virion samples Scale Bar = 250nm.
Recommended publications
  • Non-Primate Lentiviral Vectors and Their Applications in Gene Therapy for Ocular Disorders

    Non-Primate Lentiviral Vectors and Their Applications in Gene Therapy for Ocular Disorders

    viruses Review Non-Primate Lentiviral Vectors and Their Applications in Gene Therapy for Ocular Disorders Vincenzo Cavalieri 1,2,* ID , Elena Baiamonte 3 and Melania Lo Iacono 3 1 Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze Edificio 16, 90128 Palermo, Italy 2 Advanced Technologies Network (ATeN) Center, University of Palermo, Viale delle Scienze Edificio 18, 90128 Palermo, Italy 3 Campus of Haematology Franco e Piera Cutino, Villa Sofia-Cervello Hospital, 90146 Palermo, Italy; [email protected] (E.B.); [email protected] (M.L.I.) * Correspondence: [email protected] Received: 30 April 2018; Accepted: 7 June 2018; Published: 9 June 2018 Abstract: Lentiviruses have a number of molecular features in common, starting with the ability to integrate their genetic material into the genome of non-dividing infected cells. A peculiar property of non-primate lentiviruses consists in their incapability to infect and induce diseases in humans, thus providing the main rationale for deriving biologically safe lentiviral vectors for gene therapy applications. In this review, we first give an overview of non-primate lentiviruses, highlighting their common and distinctive molecular characteristics together with key concepts in the molecular biology of lentiviruses. We next examine the bioengineering strategies leading to the conversion of lentiviruses into recombinant lentiviral vectors, discussing their potential clinical applications in ophthalmological research. Finally, we highlight the invaluable role of animal organisms, including the emerging zebrafish model, in ocular gene therapy based on non-primate lentiviral vectors and in ophthalmology research and vision science in general. Keywords: FIV; EIAV; BIV; JDV; VMV; CAEV; lentiviral vector; gene therapy; ophthalmology; zebrafish 1.
  • An Overview of the Molecular Phylogeny of Lentiviruses

    An Overview of the Molecular Phylogeny of Lentiviruses

    Phylogeny of Lentiviruses 35 An overview of the molecular Reviews phylogeny of lentiviruses Brian T. Foley T10, MS K710, Los Alamos National Laboratory, Los Alamos, NM 87545 Introduction Lentiviruses are one of several groups of retroviruses. In early studies of the molecular phylogenetic analysis of endogenous and exogenous retroviruses it was suggested that the retroviruses could be divided into four groups, two complex with several accessory or regulatory genes (lentiviruses; and the bovine and primate leukemia virus group now known as deltaretrovirus) and two simple, with just the gag, pol and env genes and few or no accessory genes (a group including spumaretroviruses, C-type endogenous retroviruses and MMLV; the other group including Rous Sarcoma virus, HERV-K Simian Retrovirus 1 and MMTV) [1–5]. A more recent study, including many more recently discovered exogenous and endogenous retroviruses, illustrates the diversity of retroviruses [6]. The retroviridae are currently officially classified into seven different genera, according to the Seventh Report of the International Committee on Taxonomy of Viruses, 2000 (http://www.ncbi.nlm.nih.gov/ICTV). The seven genera are named alpha through epsilon retroviruses plus lentiviruses and spumaviruses. Phylogenetic trees based on pol gene sequences can be found in several recent papers[6–8]. None of the retroviruses in either group of complex retroviruses have been found in an endogenous state to date. Within the Lentiviruses, the primate lentiviruses discovered to date form a monophyletic cluster (Figure 1). One notable difference between the primate lentiviruses and the non-primate lentiviruses is that all nonprimate lentiviruses, except the BIV/JDV lineage, contain a region of the pol gene encoding a dUTPase, whereas all primate lentiviruses lack this region of pol.
  • Guide for Common Viral Diseases of Animals in Louisiana

    Guide for Common Viral Diseases of Animals in Louisiana

    Sampling and Testing Guide for Common Viral Diseases of Animals in Louisiana Please click on the species of interest: Cattle Deer and Small Ruminants The Louisiana Animal Swine Disease Diagnostic Horses Laboratory Dogs A service unit of the LSU School of Veterinary Medicine Adapted from Murphy, F.A., et al, Veterinary Virology, 3rd ed. Cats Academic Press, 1999. Compiled by Rob Poston Multi-species: Rabiesvirus DCN LADDL Guide for Common Viral Diseases v. B2 1 Cattle Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 2 Deer and Small Ruminants Please click on the principle system involvement Generalized viral disease Respiratory viral disease Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 3 Swine Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 4 Horses Please click on the principle system involvement Generalized viral diseases Neurological viral diseases Respiratory viral diseases Enteric viral diseases Abortifacient/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 5 Dogs Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Back to the Beginning DCN LADDL Guide for Common Viral Diseases v.
  • LENTIVIRUS and LENTIVIRAL VECTORS

    LENTIVIRUS and LENTIVIRAL VECTORS

    LENTIVIRUS and LENTIVIRAL VECTORS Risk Group: 3 I. Background and Health Hazards Lentiviruses are a subset of retroviruses that have the ability to integrate into host chromosomes and to infect non-dividing cells, and include human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) which can infect humans. Another commonly used lentivirus that is infectious to animals, but not humans, is feline immunodeficiency virus (FIV). Lentiviral vectors consist of recombinant or synthetic nucleic acid sequences and HIV or other lentivirus- based viral packaging and regulatory sequences flanked by either wild-type or chimeric long terminal repeat (LTR) regions. Use of these vector systems is particularly desirable because of their ability to integrate transgenes into dividing, as well as, non-dividing cells. However, there are risks associated with working with lentiviral vectors and these must be carefully evaluated. The two major risks are: 1) the potential generation of replication competent lentivirus (RCL); and 2) the potential for oncogenesis. These risks are largely based upon the vector system used and the transgene insert encoded by the vector. Therefore, it is imperative that prior to utilizing a lentiviral vector system, a risk assessment must be reviewed and documented. Also, because construction and/or use of lentiviral vectors falls under the definition of r/sNA research as outlined in the NIH Guidelines, possession must be reported in the workplace’s biological agent inventory and experiments must be submitted for review and approval by the site IBC prior to initiation. II. MODES OF TRANSMISSION Lentivirus is transmissible through injection, ingestion, exposure to broken skin or contact with mucous membranes of the eyes, nose and mouth.
  • The Expression of Human Endogenous Retroviruses Is Modulated by the Tat Protein of HIV‐1

    The Expression of Human Endogenous Retroviruses Is Modulated by the Tat Protein of HIV‐1

    The Expression of Human Endogenous Retroviruses is modulated by the Tat protein of HIV‐1 by Marta Jeannette Gonzalez‐Hernandez A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Immunology) in The University of Michigan 2012 Doctoral Committee Professor David M. Markovitz, Chair Professor Gary Huffnagle Professor Michael J. Imperiale Associate Professor David J. Miller Assistant Professor Akira Ono Assistant Professor Christiane E. Wobus © Marta Jeannette Gonzalez‐Hernandez 2012 For my family and friends, the most fantastic teachers I have ever had. ii Acknowledgements First, and foremost, I would like to thank David Markovitz for his patience and his scientific and mentoring endeavor. My time in the laboratory has been an honor and a pleasure. Special thanks are also due to all the members of the Markovitz laboratory, past and present. It has been a privilege, and a lot of fun, to work near such excellent scientists and friends. You all have a special place in my heart. I would like to thank all the members of my thesis committee for all the valuable advice, help and jokes whenever needed. Our collaborators from the Bioinformatics Core, particularly James Cavalcoli, Fan Meng, Manhong Dai, Maureen Sartor and Gil Omenn gave generous support, technical expertise and scientific insight to a very important part of this project. Thank you. Thanks also go to Mariana Kaplan’s and Akira Ono’s laboratory for help with experimental designs and for being especially generous with time and reagents. iii Table of Contents Dedication ............................................................................................................................ ii Acknowledgements ............................................................................................................. iii List of Figures ...................................................................................................................
  • HIV 101: Pathogenesis and Treatment

    HIV 101: Pathogenesis and Treatment

    HIV 101: Pathogenesis and Treatment Stephen Raffanti MD MPH Professor of Medicine Vanderbilt University School of Medicine . Dr. Raffanti has no financial disclosures to make. Objectives . After this presentation the attendee should be able to: . Describe current issues in the epidemiology of the HIV epidemic. Describe the life cycle of HIV; . Describe the way that HIV interacts with its host, producing disease. Describe the principles of treatment. Describe Acute HIV infection . Describe the initial evaluation of an HIV infected patient Testing, linkage to care, effective treatment and effective PrEP could stop the epidemic today. Percentages of Diagnoses of HIV Infection among Adults and Adolescents, by Region and Population of Area of Residence, 2015—United States Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Data for the year 2015 are preliminary and based on 6 months reporting delay. Data exclude persons whose county of residence is unknown. Percentages of Diagnoses of HIV Infection among Adults and Adolescents, by Population of Area of Residence and Age at Diagnosis, 2015—United States Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Data for the year 2015 are preliminary and based on 6 months reporting delay. Data exclude persons whose county of residence is unknown. Diagnoses of HIV Infection among Men Who Have Sex with Men, by Age Group, 2010–2014—United States and 6 Dependent Areas Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been statistically adjusted to account for reporting delays and missing transmission category, but not for incomplete reporting.
  • Enhancement of Antitumor Activity of Gammaretrovirus Carrying IL-12

    Enhancement of Antitumor Activity of Gammaretrovirus Carrying IL-12

    Cancer Gene Therapy (2010) 17, 37–48 r 2010 Nature Publishing Group All rights reserved 0929-1903/10 $32.00 www.nature.com/cgt ORIGINAL ARTICLE Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy Y-S Tsai1,2,3, A-L Shiau1,4, Y-F Chen4, H-T Tsai3, T-S Tzai3 and C-L Wu1,5 1Institute of Clinical Medicine, National Cheng Kung University Medical College, Tainan, Taiwan; 2Department of Urology, National Cheng Kung University Hospital, Dou-Liou Branch, Yunlin, Taiwan; 3Department of Urology, National Cheng Kung University Medical College, Tainan, Taiwan; 4Department of Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan and 5Department of Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan The objective of this study was to develop an HER2-targeted, envelope-modified Moloney murine leukemia virus (MoMLV)-based gammaretroviral vector carrying interleukin (IL)-12 gene for bladder cancer therapy. It displayed a chimeric envelope protein containing a single-chain variable fragment (scFv) antibody to the HER2 receptor and carried the mouse IL-12 gene. The fragment of anti-erbB2scFv was constructed into the proline-rich region of the viral envelope of the packaging vector lacking a transmembrane subunit of the carboxyl terminal region of surface subunit. As compared with envelope-unmodified gammaretroviruses, envelope- modified ones
  • Toll-Like Receptor and Cytokine Responses to Infection with Endogenous and Exogenous Koala Retrovirus, and Vaccination As a Control Strategy

    Toll-Like Receptor and Cytokine Responses to Infection with Endogenous and Exogenous Koala Retrovirus, and Vaccination As a Control Strategy

    Review Toll-Like Receptor and Cytokine Responses to Infection with Endogenous and Exogenous Koala Retrovirus, and Vaccination as a Control Strategy Mohammad Enamul Hoque Kayesh 1,2 , Md Abul Hashem 1,3,4 and Kyoko Tsukiyama-Kohara 1,4,* 1 Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan; [email protected] (M.E.H.K.); [email protected] (M.A.H.) 2 Department of Microbiology and Public Health, Faculty of Animal Science and Veterinary Medicine, Patuakhali Science and Technology University, Barishal 8210, Bangladesh 3 Department of Health, Chattogram City Corporation, Chattogram 4000, Bangladesh 4 Laboratory of Animal Hygiene, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan * Correspondence: [email protected]; Tel.: +81-99-285-3589 Abstract: Koala populations are currently declining and under threat from koala retrovirus (KoRV) infection both in the wild and in captivity. KoRV is assumed to cause immunosuppression and neoplastic diseases, favoring chlamydiosis in koalas. Currently, 10 KoRV subtypes have been identified, including an endogenous subtype (KoRV-A) and nine exogenous subtypes (KoRV-B to KoRV-J). The host’s immune response acts as a safeguard against pathogens. Therefore, a proper understanding of the immune response mechanisms against infection is of great importance for Citation: Kayesh, M.E.H.; Hashem, the host’s survival, as well as for the development of therapeutic and prophylactic interventions. M.A.; Tsukiyama-Kohara, K. Toll-Like A vaccine is an important protective as well as being a therapeutic tool against infectious disease, Receptor and Cytokine Responses to Infection with Endogenous and and several studies have shown promise for the development of an effective vaccine against KoRV.
  • Lentivirus Vector Fact Sheet

    Lentivirus Vector Fact Sheet

    LENTIVIRUS VECTOR FACT SHEET LENTIVIRUSES: Lentiviral vector constructs are derived from HIV and are therefore highly efficient vehicles for in vivo gene delivery. Use of these vector systems is particularly desirable because of their ability to integrate transgenes into dividing, as well as, non-dividing cells. However, there are risks associated with working with lentiviral vectors and these must be carefully evaluated. The two major risks are: 1) the potential generation of replication competent virus; and 2) the potential for oncogenesis through insertional mutagenesis. These risks are largely based upon the vector system used and the transgene insert encoded by the vector. Therefore, it is imperative that prior to utilizing a lentiviral vector system, a risk assessment must be completed and documented. Also, because construction and/or use of lentiviral vectors falls under the definition of rDNA research as outlined in the NIH Recombinant DNA Guidelines, possession must be reported in the workplace’s biological agent inventory and experiments must be submitted for review and approval by the site IBC prior to initiation. Typically, lentiviral vectors may be safely handled using either BSL-2 or BSL-2 enhanced controls depending upon the risk assessment. LENTIVIRAL VECTORS: Lentiviruses can infect not only dividing, but also non-dividing host cells, because their pre-integration complex (virus “shell”) can get through the intact membrane of the nucleus of the target cell. Lentiviral vectors can be used to provide highly effective gene therapy as they can provide long-term expression of the vectored transgene in target cells. First-generation lentiviral vectors were manufactured using a single vector packaging system that contained all HIV genes, except the envelope (env) gene, in one plasmid.
  • VMC 321: Systematic Veterinary Virology Retroviridae Retro: from Latin Retro,"Backwards”

    VMC 321: Systematic Veterinary Virology Retroviridae Retro: from Latin Retro,"Backwards”

    VMC 321: Systematic Veterinary Virology Retroviridae Retro: from Latin retro,"backwards” - refers to the activity of reverse RETROVIRIDAE transcriptase and the transfer of genetic information from RNA to DNA. Retroviruses Viral RNA Viral DNA Viral mRNA, genome (integrated into host genome) Reverse (retro) transfer of genetic information Usually, well adapted to their hosts Endogenous retroviruses • RNA viruses • single stranded, positive sense, enveloped, icosahedral. • Distinguished from all other RNA viruses by presence of an unusual enzyme, reverse transcriptase. Retroviruses • Retro = reversal • RNA is serving as a template for DNA synthesis. • One genera of veterinary interest • Alpharetrovirus • • Family - Retroviridae • Subfamily - Orthoretrovirinae [Ortho: from Greek orthos"straight" • Genus -. Alpharetrovirus • Genus - Betaretrovirus Family- • Genus - Gammaretrovirus • Genus - Deltaretrovirus Retroviridae • Genus - Lentivirus [ Lenti: from Latin lentus, "slow“ ]. • Genus - Epsilonretrovirus • Subfamily - Spumaretrovirinae • Genus - Spumavirus Retroviridae • Subfamily • Orthoretrovirinae • Genus • Alpharetrovirus Alpharetrovirus • Species • Avian leukosis virus(ALV) • Rous sarcoma virus (RSV) • Avian myeloblastosis virus (AMV) • Fujinami sarcoma virus (FuSV) • ALVs have been divided into 10 envelope subgroups - A , B, C, D, E, F, G, H, I & J based on • host range Avian • receptor interference patterns • neutralization by antibodies leukosis- • subgroup A to E viruses have been divided into two groups sarcoma • Noncytopathic (A, C, and E) • Cytopathic (B and D) virus (ALV) • Cytopathic ALVs can cause a transient cytotoxicity in 30- 40% of the infected cells 1. The viral envelope formed from host cell membrane; contains 72 spiked knobs. 2. These consist of a transmembrane protein TM (gp 41), which is linked to surface protein SU (gp 120) that binds to a cell receptor during infection. 3. The virion has cone-shaped, icosahedral core, Structure containing the major capsid protein 4.
  • Effects of Retroviruses on Host Genome Function

    Effects of Retroviruses on Host Genome Function

    ANRV361-GE42-20 ARI 1 August 2008 18:2 V I E E W R S I E N C N A D V A Effects of Retroviruses on Host Genome Function Patric Jern and John M. Coffin Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111; email: [email protected], John.Coffi[email protected] Annu. Rev. Genet. 2008. 42:20.1–20.23 Key Words The Annual Review of Genetics is online at Human Endogenous Retrovirus, LTR, transcription, recombination, genet.annualreviews.org methylation This article’s doi: 10.1146/annurev.genet.42.110807.091501 Abstract Copyright c 2008 by Annual Reviews. For millions of years, retroviral infections have challenged vertebrates, All rights reserved occasionally leading to germline integration and inheritance as ERVs, 0066-4197/08/1201-0001$20.00 genetic parasites whose remnants today constitute some 7% to 8% of the human genome. Although they have had significant evolutionary side effects, it is useful to view ERVs as fossil representatives of retro- viruses extant at the time of their insertion into the germline, not as direct players in the evolutionary process itself. Expression of particu- lar ERVs is associated with several positive physiological functions as well as certain diseases, although their roles in human disease as etio- logical agents, possible contributing factors, or disease markers—well demonstrated in animal models—remain to be established. Here we discuss ERV contributions to host genome structure and function, in- cluding their ability to mediate recombination, and physiological effects on the host transcriptome resulting from their integration, expression, and other events.
  • Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-Cov-2 Spike Protein for Neutralization Assays

    Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-Cov-2 Spike Protein for Neutralization Assays

    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.20.051219; this version posted April 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 of 15 Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays Katharine H.D. Crawford 1,2,3, Rachel Eguia 1, Adam S. Dingens 1, Andrea N. Loes 1, Keara D. Malone 1, Caitlin R. Wolf 4, Helen Y. Chu 4, M. Alejandra Tortorici 5,6, David Veesler 5, Michael Murphy 7, Deleah Pettie 7, Neil P. King 5,7, Alejandro B. Balazs 8, and Jesse D. Bloom 1,2,9,* 1 Division of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; [email protected] (K.D.C.), [email protected] (R.E.), [email protected] (A.S.D.), [email protected] (K.M.), [email protected] (A.N.L.) 2 Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA 3 Medical Scientist Training Program, University of Washington, Seattle, WA 98195, USA 4 Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA; [email protected] (C.R.W.), [email protected] (H.Y.C.) 5 Department of Biochemistry, University of Washington, Seattle, WA 98109, USA; [email protected] (M.A.T.), [email protected] (D.V.), [email protected] (M.M.), [email protected] (D.P.), [email protected] (N.P.K.) 6 Institute